WebShift Pharmaceuticals, a privately held company that is developing antisense oligonucleotides (ASOs) to treat a variety of genetic disorders, and the Charcot-Marie … Web19 jan. 2024 · Ionis Pharmaceuticals (IONS) announced topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's (AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy, or ATTRv-PN, a debilitating and potentially fatal disease that leads to peripheral nerve …
Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
Web6 dec. 2024 · As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective. Web13 mrt. 2024 · Executive Director at Ionis Pharmaceuticals . Hien Zhao is an Executive Director at Ionis Pharmaceuticals based in Carlsbad, California. Previously, Hien was a Post-Doctoral Research Fellow at University of Pennsylvania and also held positions at Washington University School of Medicine in St. Louis. Hien received a Bachelor of … port town party 2022
A Study to Evaluate the Safety and Efficacy of ION373 in …
Web30 sep. 2024 · Third quarter results reflect Ionis' focus on its strategic objectives $133 millionin total revenues $185 millionof operating expenses on a non-GAAP basis(1)and … Web22 feb. 2024 · CARLSBAD, Calif., Feb. 22, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), a genetic medicines company, today reported … Web22 dec. 2024 · Armatus Bio to Lead Development of CMT1A Gene Therapy. by Patricia Inácio, PhD December 22, 2024. Armatus Bio will now further develop a potential gene therapy for Charcot-Marie-Tooth disease type 1A ( CMT1A ), aiming to conduct clinical trials. According to a press release from the CMT Research Foundation, which has been … port town on the english channel